EP3038620 - AGENT FOR THE TREATMENT AND PREVENTION OF CANCER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 21.06.2019 Database last updated on 24.08.2024 | |
Former | Examination is in progress Status updated on 05.10.2018 | Most recent event Tooltip | 21.06.2019 | Application deemed to be withdrawn | published on 24.07.2019 [2019/30] | Applicant(s) | For all designated states Daiichi Sankyo Co., Ltd. 3-5-1, Nihonbashi-honcho Chuo-ku Tokyo 103-8426 / JP | [2016/27] | Inventor(s) | 01 /
MERCURI, Michele 6 Allenby Lane Scotch Plains, New Jersey 07076 / US | [2016/27] | Representative(s) | Nieuwenhuys, William Francis Marks & Clerk LLP 15 Fetter Lane London EC4A 1BW / GB | [N/P] |
Former [2016/27] | Nieuwenhuys, William Francis Marks & Clerk LLP 90 Long Acre London WC2E 9RA / GB | Application number, filing date | 14766221.7 | 21.08.2014 | [2016/27] | WO2014IB64006 | Priority number, date | US201361871389P | 29.08.2013 Original published format: US 201361871389 P | [2016/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015028919 | Date: | 05.03.2015 | Language: | EN | [2015/09] | Type: | A1 Application with search report | No.: | EP3038620 | Date: | 06.07.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.03.2015 takes the place of the publication of the European patent application. | [2016/27] | Search report(s) | International search report - published on: | EP | 05.03.2015 | Classification | IPC: | A61K31/429, A61K31/727, A61K45/06, A61K9/00, A61P35/00, A61P35/02, A61P35/04 | [2016/27] | CPC: |
A61K31/444 (EP,US);
A61K31/429 (EP,US);
A61K31/727 (EP,US);
A61K45/06 (EP,US);
A61N5/10 (US);
A61P35/00 (EP);
A61P35/02 (EP);
A61P35/04 (EP);
A61P43/00 (EP);
A61P7/02 (EP)
(-)
| C-Set: |
A61K31/429, A61K2300/00 (EP,US);
A61K31/727, A61K2300/00 (US,EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/27] | Title | German: | MITTEL ZUR BEHANDLUNG UND PRÄVENTION VON KREBS | [2016/27] | English: | AGENT FOR THE TREATMENT AND PREVENTION OF CANCER | [2016/27] | French: | AGENT POUR LE TRAITEMENT ET LA PRÉVENTION DU CANCER | [2016/27] | Entry into regional phase | 09.02.2016 | National basic fee paid | 09.02.2016 | Designation fee(s) paid | 09.02.2016 | Examination fee paid | Examination procedure | 09.02.2016 | Examination requested [2016/27] | 13.10.2016 | Amendment by applicant (claims and/or description) | 08.10.2018 | Despatch of a communication from the examining division (Time limit: M04) | 19.02.2019 | Application deemed to be withdrawn, date of legal effect [2019/30] | 15.03.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/30] | Fees paid | Renewal fee | 11.08.2016 | Renewal fee patent year 03 | 14.08.2017 | Renewal fee patent year 04 | 10.08.2018 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2008033887 (NUVELO INC [US], et al) [X] 1-4,10-15,18-24,30-35,37,38 * page 3, line 18 - page 6, line 6 * * page 12, lines 16-24 * * page 21, line 17 - page 23, line 6 * * page 29, lines 12-19 *; | [X]EP0404055 (MERRELL DOW PHARMA [US]) [X] 1,8-15,18,19,28-35,37 * page 2, lines 1-3, 25-30, 37-41 * * page 5, line 48 - page 6, line 28 *; | [X]WO2010030983 (AUSPEX PHARMACEUTICALS INC [US], et al) [X] 1,8,9,12-14,18,19,28,29,32-34,36-38 * page 1, paragraphs 2-3 * * page 5, paragraph 14 * * page 18, paragraph 69 * * page 21, paragraphs 83-85 * * page 22, paragraph 87 - page 23 *; | [I]WO2013014107 (AVENTIS PHARMA SA [FR], et al) [I] 1-38 * page 1, line 1 - page 3, line 5 * * page 5, lines 14-19 * * tables 3, 5-9 *; | [I]EP2374456 (DAIICHI SANKYO CO LTD [JP]) [I] 1-38 * page 3, paragraphs 1-4 * * page 4, paragraphs 7-10 * * page 5, paragraph 13 * * page 7, paragraph 19 - page 8, paragraph 20 *; | [I] - VAN DOORMAAL ET AL, "Development in anticoagulant therapy", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, (20071126), vol. 66, no. 2, ISSN 1040-8428, pages 145 - 154, XP022575956 [I] 1-38 * abstract * * page 147, column 2, paragraph 4 - page 149, column 1, paragraph 3 * * page 150, column 2, paragraphs 3-4 * * page 151, column 1, paragraph 4 * * page 151, column 2, paragraph 3 * | [I] - Clinicaltrials.gov, "Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).", (20130604), Waybackmachine internet archive, URL: http://web.archive.org/web/20130604024806/http://clinicaltrials.gov/show/NCT00986154, (20141104), XP002733049 [I] 1-38 * the whole document * | [XP] - HOKUSAI-VTE INVESTIGATORS ET AL, "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.", THE NEW ENGLAND JOURNAL OF MEDICINE 10 OCT 2013, (20131010), vol. 369, no. 15, ISSN 1533-4406, pages 1406 - 1415, XP002733050 [XP] 1-38 * the whole document * * table 1 * DOI: http://dx.doi.org/10.1056/NEJMoa1306638 | by applicant | US7365205 | - T. FURUGOHRI ET AL., "D-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles", J. THROMBOSIS AND HAEMOSTASIS, (2008), vol. 6, doi:doi:10.1111/J.1538-7836.2008.03064.X, pages 1542 - 49, XP002659799 DOI: http://dx.doi.org/10.1111/J.1538-7836.2008.03064.X | - S.M. BARGE ET AL., "Pharmaceutical Salts", J. PHARM. SCI., (1977), vol. 66, pages 1 - 19 | - FIESSINGER ET AL., JAMA, (2005), vol. 293, page 681 | - BULLER ET AL., NEJM, (2007), vol. 357, page 1094 |